9987 Carver Road
About Aerpio TherapeuticsAerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.
Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-a (HIF1-a) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-a stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.
The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.
36 articles with Aerpio Therapeutics
Since it first launched with $100 million in the bank earlier this year, Gossamer Bio has been on something of a roll.
Aerpio Pharmaceuticals Announces Uplisting to Nasdaq Capital Market and Pricing of $45.0 Million Public Offering of Common Stock
Aerpio will begin trading on the Nasdaq Capital Market under the symbol “ARPO” at the opening of trading on June 26, 2018
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
AKB-4924 is a once-daily, oral, gut-restricted HIF-1 alpha stabilizer that has been shown to improve disease indices in multiple models of inflammatory bowel disease.
TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track
TIME-2b Clinical Trial of AKB-9778 in patients with diabetic retinopathy remains on track
Mr. Rogers has more than 25 years of experience in the biopharmaceutical industry, serving as Chief Financial Officer (CFO) of five publicly-traded healthcare companies.
As of September 30, 2017, cash and cash equivalents totaled $24.8 million.
Aerpio Announces Appointment Of Stephen Hoffman, M.D., Ph.D., As Chief Executive Officer And To The Board Of Directors And The Transition Of Joseph H. Gardner, Ph.D., To President And Founder
Aerpio Announces Initiation Of Patient Dosing In The TIME-2b Study, A Phase IIb Clinical Trial Of Lead Candidate AKB-9778 In Patients With Diabetic Retinopathy
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD)
Aerpio Reports Peer-Reviewed Publication Of Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial
Aerpio Announces Presentation Of Positive Results Of AKB-9778 In Patients With Diabetic Retinopathy From TIME-2 Phase IIa Study
Aerpio Reports Positive Clinical Results From The Phase IIa Study Of Lead Candidate, AKB-9778, In Diabetic Macular Edema (DME): The TIME-2 Trial